Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
B: Arm Label: ranibizumab 0.5mg Q4; Type: ACTIVE_COMPARATOR; Interventions: Biological: ranibizumab | Arm Label: aflibercept injection 2.0mg Q4; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Arm Label: aflibercept injection 0.5mg Q4; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Arm Label: aflibercept injection 2.0mg Q8; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Intervention Type: BIOLOGICAL; Name: ranibizumab; Assigned to Arm(s): ranibizumab 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 2.0mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 2.0mg Q8
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: Ranibizumab 0.5mg Q4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8

Answer: C